Insights into incretin-based therapies for treatment of diabetic dyslipidemia

被引：29
作者：
Stemmer, Kerstin [1 ,2 ,3 ,4 ]
Finan, Brian [5 ]
DiMarchi, Richard D. [6 ]
Tschoep, Matthias H. [1 ,2 ,3 ,7 ]
Mueller, Timo D. [1 ,2 ,3 ,8 ]
机构：
[1] Helmholtz Zentrum Munchen, Inst Diabet & Obes, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany
[2] Helmholtz Zentrum Munchen, Helmholtz Diabet Ctr, Neuherberg, Germany
[3] Helmholtz Zentrum Munchen, German Ctr Diabet Res DZD, Neuherberg, Germany
[4] Univ Konstanz, Dept Biol, Constance, Germany
[5] Novo Nordisk Res Ctr Indianapolis, Indianapolis, IN 46241 USA
[6] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA
[7] Tech Univ Munich, Dept Med, Div Metab Dis, Munich, Germany
[8] Karls Univ Hosp & Clin, Eberhard Inst Expt & Clin Pharmacol & Pharmacogen, Dept Pharmacol Expt Therapy & Toxicol, D-72076 Tubingen, Germany
来源：
ADVANCED DRUG DELIVERY REVIEWS | 2020年 / 159卷
基金：
欧洲研究理事会;
关键词：
Incretins; Lipoproteins; Dyslipidemia; Diabetes; Obesity; GLUCAGON-LIKE PEPTIDE-1; GASTRIC-INHIBITORY POLYPEPTIDE; DEPENDENT INSULINOTROPIC POLYPEPTIDE; LIPOPROTEIN-LIPASE ACTIVITY; LOW-DENSITY-LIPOPROTEIN; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; IMPAIRED GLUCOSE-TOLERANCE; BROWN ADIPOSE-TISSUE; HIGH-FAT; RECEPTOR AGONIST;
D O I：
10.1016/j.addr.2020.05.008
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia. (C) 2020 Published by Elsevier B.V.
引用
收藏
页码：34 / 53
页数：20
相关论文
共 266 条
[1]   Intestinal lipoprotein overproduction in insulin-resistant states [J].
Adeli, Khosrow ;
Lewis, Gary F. .
CURRENT OPINION IN LIPIDOLOGY, 2008, 19 (03) :221-228
[2]  
AGARWALA G C, 1986, Indian Journal of Physiology and Pharmacology, V30, P280
[3]   Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT [J].
Alssema, Marjan ;
Rijkelijkhuizen, Josina M. ;
Holst, Jens J. ;
Teerlink, Tom ;
Scheffer, Peter G. ;
Eekhoff, Elisabeth M. W. ;
Gastaldelli, Amalia ;
Mari, Andrea ;
Hart, Leen M't ;
Nijpels, Giel ;
Dekker, Jacqueline M. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 169 (04) :421-430
[4]   Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet [J].
Althage, Matthew C. ;
Ford, Eric L. ;
Wang, Songyan ;
Tso, Patrick ;
Polonsky, Kenneth S. ;
Wice, Burton M. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (26) :18365-18376
[5]   MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study [J].
Ambery, Philip ;
Parker, Victoria E. ;
Stumvoll, Michael ;
Posch, Maximilian G. ;
Heise, Tim ;
Plum-Moerschel, Leona ;
Tsai, Lan-Feng ;
Robertson, Darren ;
Jain, Meena ;
Petrone, Marcella ;
Rondinone, Cristina ;
Hirshberg, Boaz ;
Jermutus, Lutz .
LANCET, 2018, 391 (10140) :2607-2618
[6]   EFFECT OF INTRAVENOUSLY INFUSED PORCINE GIP ON SERUM-INSULIN IN OBESE AND LEAN SUBJECTS STUDIED WITH THE HYPERGLYCEMIC CLAMP TECHNIQUE [J].
AMLAND, PF ;
JORDE, R ;
BURHOL, PG ;
GIERCKSKY, KE .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1985, 20 (03) :309-314
[7]   Insulin receptor isoform switching in intestinal stem cells, progenitors, differentiated lineages and tumors: evidence that IR-B limits proliferation [J].
Andres, Sarah F. ;
Simmons, James G. ;
Mah, Amanda T. ;
Santoro, M. Agostina ;
Van Landeghem, Laurianne ;
Lund, P. Kay .
JOURNAL OF CELL SCIENCE, 2013, 126 (24) :5645-5656
[8]   Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? [J].
Arafat, A. M. ;
Kaczmarek, P. ;
Skrzypski, M. ;
Pruszynska-Oszmalek, E. ;
Kolodziejski, P. ;
Szczepankiewicz, D. ;
Sassek, M. ;
Wojciechowicz, T. ;
Wiedenmann, B. ;
Pfeiffer, A. F. H. ;
Nowak, K. W. ;
Strowski, M. Z. .
DIABETOLOGIA, 2013, 56 (03) :588-597
[9]   Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4 [J].
Arakawa, Masayuki ;
Mita, Tomoya ;
Azuma, Kosuke ;
Ebato, Chie ;
Goto, Hiromasa ;
Nomiyama, Takashi ;
Fujitani, Yoshio ;
Hirose, Takahisa ;
Kawamori, Ryuzo ;
Watada, Hirotaka .
DIABETES, 2010, 59 (04) :1030-1037
[10]   Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes [J].
Ariel, D. ;
Kim, S. H. ;
Abbasi, F. ;
Lamendola, C. A. ;
Liu, A. ;
Reaven, G. M. .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2014, 24 (12) :1317-1322
12345678910